These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15181054)

  • 1. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
    Ganie MA; Khurana ML; Eunice M; Gupta N; Gulati M; Dwivedi SN; Ammini AC
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2756-62. PubMed ID: 15181054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
    Alpañés M; Álvarez-Blasco F; Fernández-Durán E; Luque-Ramírez M; Escobar-Morreale HF
    Eur J Endocrinol; 2017 Nov; 177(5):399-408. PubMed ID: 28912358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A; Agarwal N
    J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.
    Fulghesu AM; Romualdi D; Di Florio C; Sanna S; Tagliaferri V; Gambineri A; Tomassoni F; Minerba L; Pasquali R; Lanzone A
    Hum Reprod; 2012 Oct; 27(10):3057-66. PubMed ID: 22786777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
    Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A
    Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
    Petrányi G; Zaoura-Petrányi M
    Orv Hetil; 2011 Apr; 152(16):628-32. PubMed ID: 21454179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C; Wior M; Iraci GS; Kaplan R; Torres D; Gaido MI; Wyse EP
    Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
    García-Beltran C; Cereijo R; Quesada-López T; Malpique R; López-Bermejo A; de Zegher F; Ibáñez L; Villarroya F
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32107266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
    Kulshreshtha B; Gupta N; Ganie MA; Ammini AC
    Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
    Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.